Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
May 27 2022 - 6:59PM
Dow Jones News
By Stephen Nakrosis
Bristol Myers Squibb Co. on Friday said the U.S. Food and Drug
Administration approved a pair of Opdivo-based regimens to treat
certain cancer patients.
Opdivo, or nivolumab, was approved in combination with
chemotherapy, and Opdivo plus Yervoy also received approval to be
first-line treatments for certain adult patients with esophageal
squamous cell carcinoma. The approvals were based on a Phase 3
trial showing improved overall survival versus chemotherapy alone,
Bristol Myers Squibb said.
Opdivo-based treatments are now approved for five indications in
upper gastroesophageal cancers, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 27, 2022 18:44 ET (22:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
